Introduction
Serum creatinine (SeCr) concentration is usually the sole available marker of glomerular filtration rate (GFR) in clinical practice, especially in neonatal intensive care units (NICUs) .
At birth, the newborn SeCr reflects maternal concentrations and this is because maternal creatinine equilibrates with fetal concentrations across the placenta. [1] [2] [3] However, preterm birth is often associated with gestational diseases affecting placental function and/or maternal renal function. Furthermore, some gestational diseases may also affect fetal glomerular development by inducing intrauterine growth restriction. 4 To our knowledge, no previous study has specifically explored the changes in SeCr at birth according to gestational diseases. In preterm infants born less than 32 weeks of gestational age (GA), previous reports showed that SeCr concentration had a postnatal increase with a peak between the second and the fourth day of life that was followed by a SeCr decrease. 5 Both the increased peak and the slow decrease of SeCr in smaller premies reflect decreased renal function associated with low GA. 6 Postnatal SeCr changes in preterm infants may result from tubular creatinine reabsorption in the immature kidney 7 and from a physiologically low GFR during the first days of life. 8 Moreover, in sick preterm infants, many clinical conditions inducing hypotension, hypovolemia and hypoxemia and the use of nephrotoxic drugs may lead to further reduction of GFR. 9 In particular, nonsteroidal anti-inflammatory drugs (NSAID) that are given for treatment of patent ductus arteriosus (PDA) have been reported to impair renal perfusion 10 and the immature kidney is regarded as especially sensitive to NSAID renal effects. However, hemodynamically significant PDA (hsPDA) itself can be associated with poor renal perfusion and we could speculate that the NSAID renal effects may be exacerbated by a low GFR preceding NSAID administration.
We used a regional perinatal database, to obtain additional information about maternal and neonatal factors influencing SeCr at birth and postnatal SeCr increase in a large cohort or preterm infants born less than 32 weeks of GA.
Methods

Study population
All the infants born less than 32 weeks of GA from January 2001 to December 2005 and hospitalized in our NICU were eligible for this study.
Data collection
Data on the population were obtained from our regional perinatal database 11, 12 with prospective recording of mother-infant clinical information, which was set up with the approval of the National Committee of Informatics and Liberty. A total of 661 medical records of preterm infants born less than 32 weeks of GA were identified. Information was collected about antenatal history: maternal age, hypertensive disease of pregnancy (HDP), placental abruption, placenta previa, diabetes, preterm prelabor rupture of membranes (PPROM), preterm labor, antenatal steroids administration, singleton or multiple pregnancy, abnormal fetal heart rate patterns and postnatal life: mode of delivery, 1 min Apgar score, GA, birth weight (BW), gender, appropriateness of BW for GA, early onset sepsis (EOS), need for mechanical ventilation, respiratory distress syndrome (RDS) requiring surfactant administration, hsPDA requiring medical and/or surgical treatment. The GA in completed weeks was assessed on the basis of the mother's last menstrual period and confirmed or modified when necessary by routine early antenatal ultrasound examination. The occurrence of hsPDA was defined according to echocardiographic criteria (left atrial to aortic root ratio, pulsed Doppler signal within the duct and ductal diameter). 13, 14 Owing to the NICU common standards, all the infants in the study had an echocardiography for PDA screening between days 2 and 4 of life. In case of clinically symptomatic PDA, echocardiography was performed before day 2 and similarly repeated after day 4 in case of clinical symptoms.
According to previous recommendations for water and electrolytes prescription in very low birth weight (VLBW) infants, 15 babies born less than 32 weeks of GA had daily measurements of serum electrolytes concentrations in our NICU, over the first days of life. SeCr was concurrently measured to allow a prompt diagnosis of clinically significant reduction in GFR and also to anticipate consequences of renal failure, as previously described. 16 Creatinine values available between days 1 and 7 were collected retrospectively for each patient from the hospital laboratory electronic database. Day 1 was considered to be the first morning after birth. Baseline SeCr was defined as SeCr at day 1 and SeCr peak as the highest SeCr value during the first week. Creatinine was measured by multi-enzymatic assay (amidohydrolase þ oxidase and peroxidase) with Ortho Clinical Diagnostics analyzer (Rochester, NY, US).
Statistical analysis
The normality of the distributions of SeCr was assessed with Kolmogorov-Smirnoff and Shapiro-Wilks tests. Univariate analyses were performed to correlate SeCr values and perinatal variables using one-factor analysis of variance. Variables significant at a P-level <0.20 at the univariate analysis were entered into a backward selection analysis of variance. The r 2 and the incremental r 2 were calculated. Statistical analyses were performed using SAS 8.2 (SAS Institute Inc.). All hypotheses were tested at the two-tailed 0.05 significance level. To further evaluate the independent effect of PDA on SeCr before ibuprofen treatment, our study population was divided into two groups: newborns who received ibuprofen treatment (exposed group, cases) and newborns who did not receive ibuprofen (non-exposed group, controls). These two groups were matched for GA and sex.
Results
Study population
Of the 661 infants eligible, 5 were excluded because they had major congenital malformations and 4 because of their mother's terminal or severe acute renal failure. So, the study population included 652 infants. Table 1 shows antenatal and postnatal characteristics of the study population.
Clinical data
Creatinine values and trends
Serum creatinine values were available for 89, 87, 80, 71 and 66% of infants progressing from days 1 to 5 and 53% for days 6 to 7 of life (results in Table 2 ). Figure 1 shows creatinine profile during the first week according to GA at birth. For infants p28 weeks GA, SeCr was found to decrease after reaching a peak at day 5. This peak was at day 2 for infants born between 29 and 31 weeks of GA.
Correlation with perinatal variables
Factors associated with high baseline SeCr at the univariate analysis were: cesarean section, placental abruption, abnormal fetal heart rate patterns, HDP, antenatal steroids, higher GA, SGA and advancing hour of life. Preterm labor and PPROM were associated with low baseline SeCr (data not shown). Independent variables associated with baseline SeCr at the multivariate analysis were: HDP, advancing hour of life, placental abruption and GA (Table 3 ). All these variables were positively related to baseline SeCr.
At univariate analysis, there was no statistically significant effect of the explored antenatal factors on SeCr peak (data not shown); GA at birth, ibuprofen-treated PDA, RDS requiring surfactant administration and EOS were postnatal factors associated with SeCr peak. They were all identified as independent significant variables at the multivariate analysis (Tables 2 and 4 ). GA showed a negative association, whereas PDA, RDS and EOS were positively related to SeCr peak.
Within the whole population, children with hsPDA requiring treatment showed a different SeCr profile during the first week, as they presented a SeCr peak that was higher and occurred later when compared to children without hsPDA. However, GA was significantly lower in the hsPDA group (27.9 ± 1.9 weeks) when compared to infants without hsPDA (29.2±1.7 weeks; P<0.001). So, a case-control analysis was performed to eliminate the GA confounding effect.
Case-control analysis
Of 162 infants with hsPDA, 155 had been treated by ibuprofen, 3 by indomethacin and 4 by surgical ligature (because of contraindication of medical treatment). In the subgroup analysis of 155 ibuprofen-exposed, 11 infants treated at day 1 and 21 infants without a GA-matched control were excluded. So, the remaining 123 ibuprofen-exposed infants were compared to 246 GA and sex-matched controls: SeCr value the day before ibuprofen administration was significantly higher in cases when compared to controls of similar postnatal age (P ¼ <0.0001; Table 5 ); cases and controls had the same characteristics (described in Table 1) except for incidence of RDS requiring surfactant that was higher in infants with hsPDA: 83.7 versus 65% (P<0.005, data not shown).
Discussion
Several studies have explored creatinine changes in preterm infants after birth. 5,17 -19 These studies were limited to population samples either small or not having frequent creatinine levels estimated during the first week. Among them, only one specifically investigated the role of perinatal factors in influencing SeCr values. 17 It has long been known that newborn SeCr reflects maternal SeCr at birth. 20 So, maternal creatinine concentration is expected to contribute to a great portion of the first day neonatal SeCr. After birth, SeCr increases in the first 48 h in preterm infants. 7, 8 Consistent with these data, our results showed that the main factors analyzed found to be related to baseline SeCr were HDP, a condition that is often associated with high maternal levels of SeCr, and advancing hour of life. Placental abruption and GA explained only a very small proportion of the variability of the first day neonatal SeCr in our study. Moreover, a positive correlation between SeCr at admission in NICU and GA was not observed in previous investigations. 5, 6, 8, 17, 21 Therefore, the finding of a positive correlation between GA and baseline SeCr, though statistically significant, should be interpreted with caution.
The SeCr course was strongly influenced by GA in our cohort during the first day of life. SeCr increased after birth of the preterm infant, reaching a peak that was at the second day for infants born at 29 to 31 weeks of GA and at the fifth day for those born at p28 weeks of GA. SeCr peak was found to be higher for lower GA. Our results are consistent with others: Bueva and Guignard 18 showed a negative correlation between plasma creatinine and GA in one study comparing preterm infants versus term infants between the first and the second day of life; Gallini et al. 5 found that during the first week of life, the maximum value of SeCr was significantly higher for GA lower than 27 weeks than for 27 to 28, 29 to 30 and 31 to 32 weeks GA; recently Auron and Mhanna 6 showed that in VLBW infants younger than 29 weeks or smaller than 1000 g there was a delay in the decrease of their SeCr that extended beyond the first day of life. So, gestation and age-based reference charts have been proposed for the interpretation of creatinine values in extremely premature babies <28 weeks GA. 21 Our study also disclosed EOS, RDS and ibuprofen-treated hsPDA as other independent factors associated with high postnatal SeCr increase. One recent study from Cuzzolin et al. 17 in newborns ranging from 22 to 36 weeks GA underlined that in neonates with impaired renal function, a significant increase of SeCr occurred from the third day of life, this being related to many risk factors, RDS and ibuprofen treatment being among them. These findings are consistent with the current knowledge that various clinical conditions occurring in NICU may impair neonatal renal function: Creatinine changes in preterm infants S Iacobelli et al RDS, mechanical ventilation, systemic hemodynamic compromise, acute anemia, dehydration, hypoxemia, acidosis and nephrotoxic drugs including ibuprofen. 22 We have also found that in infants with hsPDA, SeCr increase preceded ibuprofen administration, this suggesting that a renal impairment because of PDA and/or associated conditions exists before starting NSAID therapy. Concerning this point, many studies demonstrated that prophylactic or therapeutic ibuprofen, as with other cyclooxygenase inhibitors, may not be exempt from causing renal adverse effects, [23] [24] [25] but few investigations have explored the effect on renal function of PDA before and independently from ibuprofen treatment. Vanpée et al. 26 showed that sick VLBW infants having a PDA and requiring mechanical ventilation had lower creatinine clearances and significantly higher fractional sodium excretion than controls; however, their study also included few infants who had received NSAID for ductus closure before evaluating renal function. Shimada et al. 27, 28 studied the cardiocirculatory effects of hsPDA in VLBW and extremely low BW preterm with RDS and they found a significant decrease in renal blood flow in infants with hsPDA compared to controls before pharmacological closure of Figure 1 Creatinine profile during the first week of life according to gestational age (GA) in 652 infants <32 weeks of GA. Creatinine changes in preterm infants S Iacobelli et al PDA. Abnormal renal blood flows reverted after treatment and seemed less severe when early pharmacological closure of PDA was carried out. This is consistent with our finding that SeCr value before ibuprofen administration is significantly higher in infants with hsPDA compared to controls, this difference being stronger when treatment of PDA occurred later. This point needs to be further investigated in future prospective studies.
There are many limitations in our study. First of all, maternal SeCr values were not available and this limits the interpretation of the multiple regression analysis. Moreover, the lack of this information limits the interpretation of the detected correlation between baseline SeCr and HDP, a condition in which maternal SeCr may be elevated. Second, precise information about maternal exposure to drugs potentially affecting infant's renal function was not accessible for review. Third, the collection of newborns creatinine data was retrospective and we could not measure creatinine clearance or other biological parameters of renal function to correlate them with GA and with all the perinatal factors explored in this cohort. The lack of data about fluid intake, water balance and hypernatremic dehydration during the first week of life also limits the interpretation of SeCr values. Finally, some clinical data such as neonatal hypoxia, hypotension, acute anemia at birth and infants exposure to nephrotoxic drugs such as gentamicin were not assessed and they could represent factors influencing changes in SeCr in our population.
There are limitations to physiopathological interpretation of our data: the higher rate of RDS in preterm infants with hsPDA is a possible, confounding factor in the analysis of the results of the postnatal SeCr increase, as RDS represents a risk factor for elevated SeCr itself. However, the relationship between postnatal SeCr increase and hsPDA before any NSAID treatment remains valid, as hsPDA, together with GA, was the main factor analyzed in this study that was found to be related to SeCr peak, with a less contribution of RDS and EOS.
Of course, future prospective studies are necessary to explore the development of renal function in very preterm infants and also to determine whether multifactors events acting early in postnatal life could have long-term consequences on renal outcome in later life.
